

MA3 Corneal Abrasion

Percentage of patients, aged 18 years or older, who undergo anesthesia care and did not have a new diagnosis of corneal injury in the post-anesthesia care unit/recovery area.

2018 OPTIONS FOR INDIVIDUAL MEASURES:

Anesthesia Business Group QCDR, Advance QCDR, SCG Health

NATIONAL QUALITY STRATEGY DOMAIN: Person and Caregiver-Centered Experience and Outcomes

MEASURE TYPE: Outcome

DEFINITION:

Corneal Injury: Includes both exposure keratitis and corneal abrasion. For the purposes of this measure, the distinction does not need to be made with fluorescein examination of the cornea under ultraviolet light; however, it can be diagnosed in this manner. Corneal injury also includes any new symptom of eye pain treated with topical antibiotic (e.g., erythromycin) while in the post-anesthesia care unit/recovery area. Other causes of eye pain (e.g. acute angle-closure glaucoma) can be excluded by instilling one drop of local anesthetic (e.g., proparacaine) into the eye. If the pain is immediately and completely relieved, corneal injury is confirmed and acute angle-closure glaucoma is excluded.

DENOMINATOR:

All patients, aged 18 and older, who undergo anesthesia care, except those with preexisting eye trauma or those patients undergoing ophthalmologic surgery.

Denominator Criteria (Eligible Cases):

All patients aged 18 years and older who undergo anesthesia care

AND NOT

Anesthesia care described by code 00300 when the underlying surgical procedure is described by CPT Codes: 67800, 67801, 67805, 67808, 67810, 67840, 67850, 67875, 67900, or 67938

OR

Patients who undergo ophthalmologic surgery or patients with a diagnosis of either eye trauma or corneal injury before anesthesia care

OR

Organ Donors as designated by ASA Physical Status 6

NUMERATOR:

All patients who undergo anesthesia care and who do not have a new diagnosis of corneal injury in the post-anesthesia care unit/recovery area who are awake and able to be assessed.

Numerator Quality-Data Coding Options for Reporting Satisfactorily:

Performance Met:

Patient was NOT newly diagnosed with exposure keratitis or corneal abrasion in the

post-anesthesia care unit or recovery room and was awake and able to be assessed (**ASA38A**)

OR

Performance Not Met:

Patient diagnosed with new exposure keratitis or corneal abrasion in the post-anesthesia care unit or recovery room and was awake and able to be assessed (**ASA38B**)

WHAT DATA SOURCES ARE USED FOR THE MEASURE? Administrative clinical data, Claims, Paper medical record, Prescription Drug Event Data Elements, Record review, Other health information exchanges and Surescript pharmacy feeds

STEWARD: Advance QCDR (Medaxion)

OF PERFORMANCE RATES TO BE SUBMITTED IN THE XML: 1

Indicate an Overall Performance Rate if more than 1 performance rate is to be submitted: NA

INVERSE MEASURE: No

PROPORTION MEASURE SCORING OR CONTINUOUS MEASURE SCORING

RISK ADJUSTED: No

RATIONALE:

There is an abundance of peer-reviewed academic literature demonstrating the relationship between frailty and poor outcomes. With better assessment of frailty in surgical patients, there will be trends toward reevaluating surgical decision making and/or incorporating preoperative physical and occupational therapy into one's practice to improve upon frailty prior to the operation at hand.

COPYRIGHT:

The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

Advance QCDR (Medaxion) encourages use of the Measures by other health care professionals, where appropriate. Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary coding sets should obtain all necessary licenses from the owners of these code sets. Advance QCDR (Medaxion) disclaims all liability for use or accuracy of any Current

Procedural Terminology (CPT®) or other coding contained in the specifications.

This measure is in continuous development by Advance QCDR (Medaxion). The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by health care providers in connection with their practices). Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and Advance QCDR (Medaxion). Advance QCDR (Medaxion) shall not be responsible for the implementation of the Measures.

CPT® contained in the Measures specifications is copyright 2004-2018 American Medical Association. All Rights Reserved.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.